|  |
| --- |
|  |

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **April 30, 2019**

or

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_\_\_\_\_\_\_\_\_\_ to \_\_\_\_\_\_\_\_\_\_\_\_\_

Commission File Number **333-161157**

|  |
| --- |
| **PIVOT PHARMACEUTICALS INC.** |
| (Exact name of registrant as specified in its charter) |

|  |  |  |
| --- | --- | --- |
| **British Columbia** |   | **N/A** |
| (State or other jurisdiction of incorporation or organization) |   | (IRS Employer Identification No.) |

|  |  |  |
| --- | --- | --- |
| **1275 West 6th Avenue, Vancouver, British Columbia, Canada** |   | **V6H 1A6** |
| (Address of principal executive offices) |   | (Zip Code) |

|  |
| --- |
| **(514) 943-1899** |
| (Registrant’s telephone number, including area code) |

|  |
| --- |
| **N/A** |
| (Former name, former address and former fiscal year, if changed since last report) |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES    NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  YES    NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

|  |  |  |  |
| --- | --- | --- | --- |
| Large accelerated filer |  | Accelerated filer |  |
| Non-accelerated filer |  | Smaller reporting company |  |
| (Do not check if a smaller reporting company) | Emerging growth company |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)  YES    NO

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.  YES    NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

171,039,468 common shares issued and outstanding as of June 17, 2019

|  |
| --- |
|  |

|  |
| --- |
|   |
|   |
|   |
|   |

**TABLE OF CONTENTS**

|  |  |  |
| --- | --- | --- |
| [PART I – FINANCIAL INFORMATION](#PART_I_–_FINANCIAL_INFORMATION) |   |   |
|   |   |   |
| [Item 1.](#Item_1._Financial_Statements) | [Financial Statements](#Item_1._Financial_Statements) | 3 |   |
| [Item 2.](#Item_2._Management's_Discussion_and_Ana) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#Item_2._Management's_Discussion_and_Ana) | 23 |   |
| [Item 3.](#Item_3._Quantitative_and_Qualitative_Di) | [Quantitative and Qualitative Disclosure About Market Risk](#Item_3._Quantitative_and_Qualitative_Di) | 33 |   |
| [Item 4.](#Item_4._Controls_and_Procedures) | [Controls and Procedures](#Item_4._Controls_and_Procedures) | 33 |   |
|   |   |   |   |
| [PART II – OTHER INFORMATION](#PART_II_–_OTHER_INFORMATION) |   |   |
|   |   |   |
| [Item 1.](#Item_1._Legal_Proceedings) | [Legal Proceedings](#Item_1._Legal_Proceedings) | 34 |   |
| [Item 1A.](#Item_1A._Risk_Factors)  | [Risk Factors](#Item_1A._Risk_Factors) | 34 |   |
| [Item 2.](#Item_2._Unregistered_Sales_of_Equity_Se) | [Unregistered Sales of Equity Securities and Use of Proceeds](#Item_2._Unregistered_Sales_of_Equity_Se) | 34 |   |
| [Item 3.](#Item_3._Defaults_Upon_Senior_Securities) | [Defaults Upon Senior Securities](#Item_3._Defaults_Upon_Senior_Securities) | 34 |   |
| [Item 4.](#Item_4._Mine_Safety_Disclosures) | [Mine Safety Disclosures](#Item_4._Mine_Safety_Disclosures) | 34 |   |
| [Item 5.](#Item_5._Other_Information) | [Other Information](#Item_5._Other_Information) | 34 |   |
| [Item 6.](#Item_6._Exhibits) | [Exhibits](#Item_6._Exhibits) | 35 |   |
|    |   |   |   |
| [SIGNATURES](#SIGNATURES) | 38 |  |

|  |
| --- |
|   |
| 2 |
|   |
|   |

**PART I – FINANCIAL INFORMATION**

**Item 1. Financial Statements**

Our unaudited interim condensed consolidated financial statements for the period ended April 30, 2019 form part of this quarterly report. All currency references in this report are to Canadian dollars unless otherwise noted. This financial information, in the opinion of management, includes all adjustments consisting of normal recurring entries necessary for the fair presentation of such data. The results of operations for the three month period ended April 30, 2019 are not necessarily indicative of results to be expected for any subsequent period.

|  |
| --- |
|   |
| 3 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Interim Condensed Consolidated Financial Statements

(Expressed in Canadian dollars)

Three month period ended April 30, 2019 (unaudited) and 2018

|  |
| --- |
|   |
| 4 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Interim Condensed Consolidated Balance Sheets

(Expressed in Canadian dollars)

(unaudited)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **April 30,****2019****$** |  |  | **January 31,****2019****$** |   |
|   |   |   |   |   |   |   |
| Assets |   |   |   |   |   |   |
|   |   |   |   |   |   |   |
| Current assets |   |   |   |   |   |   |
|   |   |   |   |   |   |   |
| Cash |   |   | 45,414 |   |   |   | 74,800 |   |
| Tax receivable |   |   | 49,271 |   |   |   | 44,489 |   |
| Prepaid and other current assets |   |   | 99,162 |   |   |   | 122,585 |   |
|   |   |   |   |   |   |   |   |   |
| Total current assets |   |   | 193,847 |   |   |   | 241,874 |   |
|   |   |   |   |   |   |   |   |   |
| Equipment, net (Note 5) |   |   | – |   |   |   | 4,162 |   |
| Intangible assets, net (Notes 4 and 6) |   |   | 8,264,278 |   |   |   | 8,349,822 |   |
| Right-of-use asset (Note 7) |   |   | 1,091,148 |   |   |   | – |   |
|   |   |   |   |   |   |   |   |   |
| Total assets |   |   | 9,549,273 |   |   |   | 8,595,858 |   |
|   |   |   |   |   |   |   |   |   |
| Liabilities and Stockholders’ Equity  |   |   |   |   |   |   |   |   |
|   |   |   |   |   |   |   |   |   |
| Current liabilities  |   |   |   |   |   |   |   |   |
|   |   |   |   |   |   |   |   |   |
| Accounts payable and accrued liabilities |   |   | 1,273,403 |   |   |   | 667,493 |   |
| Due to related parties (Note 14) |   |   | 407,928 |   |   |   | 330,483 |   |
| Convertible debenture, net (Note 8) |   |   | 2,659,375 |   |   |   | 3,497,599 |   |
| Promissory note (Note 9) |   |   | 270,666 |   |   |   | – |   |
| Acquisition obligation (Note 4(b)) |   |   | 456,382 |   |   |   | 432,923 |   |
| Deferred revenues |   |   | – |   |   |   | 157,728 |   |
| Lease liability (Note 7) |   |   | 249,082 |   |   |   | – |   |
|   |   |   |   |   |   |   |   |   |
| Total current liabilities |   |   | 5,316,836 |   |   |   | 5,086,226 |   |
|   |   |   |   |   |   |   |   |   |
| Lease liability (Note 7) |   |   | 863,926 |   |   |   | – |   |
|   |   |   |   |   |   |   |   |   |
| Total liabilities |   |   | 6,180,762 |   |   |   | 5,086,226 |   |
|   |   |   |   |   |   |   |   |   |
| Stockholders’ Equity  |   |   |   |   |   |   |   |   |
|   |   |   |   |   |   |   |   |   |
| Common stock: Unlimited shares authorized, without par value, 105,944,216 and 96,899,678 shares issued and outstanding, respectively (Note 10) |   |   | 22,953,663 |   |   |   | 21,340,273 |   |
|   |   |   |   |   |   |   |   |   |
| Common stock issuable  |   |   | – |   |   |   | 10,000 |   |
|   |   |   |   |   |   |   |   |   |
| Additional paid-in capital  |   |   | 17,024,965 |   |   |   | 16,999,265 |   |
|   |   |   |   |   |   |   |   |   |
| Accumulated other comprehensive income  |   |   | 245,145 |   |   |   | 123,429 |   |
|   |   |   |   |   |   |   |   |   |
| Accumulated deficit  |   |   | (36,855,262 | ) |   |   | (34,963,335 | ) |
|   |   |   |   |   |   |   |   |   |
| Total stockholders’ equity |   |   | 3,368,511 |   |   |   | 3,509,632 |   |
|   |   |   |   |   |   |   |   |   |
| Total liabilities and stockholders’ equity |   |   | 9,549,273 |   |   |   | 8,595,858 |   |

(The accompanying notes are an integral part of these interim condensed consolidated financial statements)

|  |
| --- |
|   |
| 5 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Interim Condensed Consolidated Statements of Operations and Comprehensive Income

(Expressed in Canadian dollars)

(Unaudited)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **Three Months** **Ended** **April 30,****2019****$** |  |  | **Three Months** **Ended** **April 30,****2018****$** |   |
|   |   |   |   |   |   |   |
| Revenue |   |   | – |   |   |   | – |   |
|   |   |   |   |   |   |   |   |   |
| Expenses |   |   |   |   |   |   |   |   |
| Amortization (Notes 5 and 6) |   |   | 241,099 |   |   |   | 165,613 |   |
| Due diligence costs |   |   | – |   |   |   | 122,672 |   |
| Foreign exchange (gain) loss |   |   | (16,825 | ) |   |   | 49,249 |   |
| General and administrative |   |   | 506,786 |   |   |   | 955,954 |   |
| Lease expense |   |   | 92,488 |   |   |   | – |   |
| Lease liability expense |   |   | 47,433 |   |   |   | – |   |
| Licensing fees |   |   | 39,963 |   |   |   | – |   |
| Professional fees |   |   | 181,649 |   |   |   | 226,169 |   |
| Research and development |   |   | 59,487 |   |   |   | 108,801 |   |
| Salaries and wages |   |   | 505,056 |   |   |   | 240,514 |   |
| Sales and marketing |   |   | – |   |   |   | 8,929 |   |
| Write-off of equipment (Note 5) |   |   | 3,901 |   |   |   | – |   |
|   |   |   |   |   |   |   |   |   |
| Total expenses |   |   | 1,661,037 |   |   |   | 1,877,901 |   |
|   |   |   |   |   |   |   |   |   |
| Loss from operations |   |   | (1,661,037 | ) |   |   | (1,877,901 | ) |
|   |   |   |   |   |   |   |   |   |
| Other income (expense) |   |   |   |   |   |   |   |   |
| Gain on repayment of promissory note (Note 9(a)) |   |   | – |   |   |   | 8,890 |   |
| Interest expense |   |   | (239,728 | ) |   |   | (201,466 | ) |
| Other income (expense) |   |   | 26,642 |   |   |   | (34,399 | ) |
|   |   |   |   |   |   |   |   |   |
| Total other income (expense) |   |   | (213,086 | ) |   |   | (226,975 | ) |
|   |   |   |   |   |   |   |   |   |
| Net loss  |   |   | (1,874,123 | ) |   |   | (2,104,876 | ) |
|   |   |   |   |   |   |   |   |   |
| Other comprehensive income (loss) |   |   |   |   |   |   |   |   |
| Foreign currency translation adjustment |   |   | (121,716 | ) |   |   | 35,106 |   |
|   |   |   |   |   |   |   |   |   |
| Net comprehensive loss |   |   | (1,995,839 | ) |   |   | (2,069,770 | ) |
|   |   |   |   |   |   |   |   |   |
| Net loss per share, basic  |   |   | (0.02 | ) |   |   | (0.03 | ) |
| Net loss per share, diluted |   |   | (0.02 | ) |   |   | (0.03 | ) |
|   |   |   |   |   |   |   |   |   |
| Weighted average shares outstanding – basic  |   |   | 99,535,678 |   |   |   | 86,209,595 |   |
| Weighted average shares outstanding –diluted |   |   | 99,535,678 |   |   |   | 86,209,595 |   |

(The accompanying notes are an integral part of these interim condensed consolidated financial statements)

|  |
| --- |
|   |
| 6 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Interim Condensed Consolidated Statements of Cash Flows

(Expressed in Canadian dollars)

(unaudited)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **Three Months****Ended****April 30,****2019****$** |  |  | **Three Months****Ended****April 30,****2018** **$** |   |
|   |   |   |   |   |   |   |
| Operating activities |   |   |   |   |   |   |
| Net loss |   |   | (1,874,123 | ) |   |   | (2,104,876 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |   |   |   |   |   |   |   |   |
| Interest accretion |   |   | 176,442 |   |   |   | 115,153 |   |
| Depreciation and amortization  |   |   | 241,099 |   |   |   | 165,613 |   |
| Expenses paid related to debt issuance |   |   | – |   |   |   | (380,770 | ) |
| Stock issued for services |   |   | 64,315 |   |   |   | 291,853 |   |
| Stock-based compensation |   |   | 5,896 |   |   |   | 34,898 |   |
| Lease expense |   |   | 3,799 |   |   |   | – |   |
| Gain on repayment of promissory note |   |   | – |   |   |   | (8,890 | ) |
| Write-off of equipment |   |   | 3,901 |   |   |   | – |   |
| Exchange (gain) / loss |   |   | 21,809 |   |   |   | (1,133 | ) |
| Changes in operating assets and liabilities: |   |   |   |   |   |   |   |   |
| Prepaids and other current assets |   |   | 18,678 |   |   |   | (85,360 | ) |
| Deposit |   |   | – |   |   |   | (250,000 | ) |
| Due to related parties |   |   | (201,659 | ) |   |   | (12,027 | ) |
| Accounts payable and accrued liabilities |   |   | 1,131,884 |   |   |   | (183,676 | ) |
| Deferred revenue |   |   | (159,852 | ) |   |   | – |   |
| Net cash used in operating activities  |   |   | (567,811 | ) |   |   | (2,419,215 | ) |
|   |   |   |   |   |   |   |   |   |
| Investing activities |   |   |   |   |   |   |   |   |
| Cash acquired through acquisition |   |   | – |   |   |   | 2,279 |   |
| Business acquisition  |   |   | – |   |   |   | (428,438 | ) |
| Net cash used in investing activities  |   |   | – |   |   |   | (426,159 | ) |
|   |   |   |   |   |   |   |   |   |
| Financing activities |   |   |   |   |   |   |   |   |
| (Repayment) of / Proceeds from convertible debenture, net |   |   | (750,000 | ) |   |   | 4,939,975 |   |
| Payment for debt modification |   |   | (250,000 | ) |   |   | – |   |
| Proceeds from issuance of units |   |   | 1,250,000 |   |   |   | – |   |
| Proceeds from / (repayment) of promissory note |   |   | 276,000 |   |   |   | (247,305 | ) |
| Repayment of loan payable |   |   | – |   |   |   | (15,925 | ) |
| Net cash provided by financing activities  |   |   | 526,000 |   |   |   | 4,676,745 |   |
|   |   |   |   |   |   |   |   |   |
| Effects of exchange rate changes on cash  |   |   | 12,425 |   |   |   | 13,113 |   |
|   |   |   |   |   |   |   |   |   |
| (Decrease) increase in cash  |   |   | (29,386 | ) |   |   | 1,844,484 |   |
| Cash – beginning of period |   |   | 74,800 |   |   |   | 79,304 |   |
|   |   |   |   |   |   |   |   |   |
| Cash – end of period |   |   | 45,414 |   |   |   | 1,923,788 |   |

Supplemental cash flow disclosures (Note 13)

(The accompanying notes are an integral part of these condensed consolidated financial statements)

|  |
| --- |
|   |
| 7 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **1.** | **Nature of Operations and Continuance of Business** |
|   |   |
|   | Pivot Pharmaceuticals Inc. (the “Company”) was incorporated in British Columbia under the Business Corporations Act on June 10, 2002. On April 7, 2015, the Company changed its name from Neurokine Pharmaceuticals Inc. to Pivot Pharmaceuticals Inc. The Company is in the business of developing and commercializing therapeutic pharmaceuticals and nutraceuticals, as well as drug delivery platform technologies.  These interim condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at April 30, 2019, the Company has not earned any revenue, has a working capital deficit of $5,122,989 and an accumulated deficit of $36,855,262. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. The Company will continue to seek financing, in the form of equity or debt, to mitigate the substantial doubt over going concern and continue to meet its obligations.  |

|  |  |
| --- | --- |
| **2.** | **Significant Accounting Policies** |

|  |  |  |
| --- | --- | --- |
|   | (a) | Basis of Presentation |
|   |   |   |
|   |   | The interim condensed consolidated financial statements and the related notes of the Company are prepared in accordance with generally accepted accounting principles in the United States and are expressed in Canadian dollars. The Company’s fiscal year-end is January 31.  |

|  |  |  |
| --- | --- | --- |
|   | (b) | Use of Estimates |
|   |   |   |
|   |   | The preparation of these interim condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  The Company regularly evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets and assumptions used to determine the fair values of stock-based compensation, warrants and warrants issued with shares units. Estimates and assumptions have also been made on the recoverable amount of intangible assets, fair value of debentures for the purpose of evaluating modification versus extinguishments, fair value of convertible debentures and deferred income tax asset. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. |

|  |
| --- |
|   |
| 8 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **2.** | **Significant Accounting Policies** (continued) |

|  |  |  |
| --- | --- | --- |
|   | (c) | Interim Financial Statements |
|   |   |   |
|   |   | These interim unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s condensed consolidated financial position, results of operations and cash flows for the periods shown. The condensed consolidated results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. Certain disclosures and financial information have been condensed in accordance with generally accepted accounting principles in the United States. These interim condensed consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K (the "2019 Form 10-K") for the year ended January 31, 2019, which was filed with the Securities and Exchange Commission (the "SEC") on May 3, 2019. |
|   |   |   |
|   | (d) | Basis of Consolidation |
|   |   |   |
|   |   | The interim condensed consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company. Control is achieved where the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The consolidating entities include:  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **% of ownership** |  |  | **Jurisdiction** |   |
|   |   |   |   |   |  |   |
| Pivot Pharmaceuticals Inc. |   | Parent |   |   | Canada |   |
| Pivot Green Stream Health Solutions Inc. |   |   | 100 | % |   | Canada |   |
| Pivot Naturals, LLC |   |   | 100 | % |   | U.S.A. |   |
| Thrudermic, LLC |   |   | 100 | % |   | U.S.A. |   |

|  |  |  |
| --- | --- | --- |
|   | (e) | Financial Instruments and Fair Value Measures |
|   |   |   |
|   |   | ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: |

Level 1: Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2: Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3: Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

|  |
| --- |
|   |
| 9 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **2.** | **Significant Accounting Policies** (continued) |
|   |   |   |
|   |   | The Company’s financial instruments consist principally of cash, accounts payable and accrued liabilities, due to related parties, convertible debenture, promissory note and acquisition obligation. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. |

|  |  |  |
| --- | --- | --- |
|   | (f) | Loss Per Share |
|   |   |   |
|   |   | The Company computes net loss per share in accordance with ASC 260, Earnings Per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the condensed consolidated statement of operations and comprehensive loss. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. During the period ended April 30, 2019, the Company has excluded 13,681,426 (January 31, 2019 – 3,249,700) potential dilutive shares. For the three month periods ended April 30, 2019 and 2018, diluted loss per share is equivalent to basic loss per share because the potential exercise of the equity-based financial instruments was anti-dilutive. |

|  |  |  |
| --- | --- | --- |
|   | (g) | Adoption of new accounting principles |
|   |   |   |
|   |   | In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASC 842 which requires lessees to recognize a right-of-use (“ROU”) asset and lease liability on the balance sheet for virtually all leases. On February 1, 2019, the Company adopted ASC 842 and all related amendments using the modified retrospective transition approach. Refer to Note 3.   In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. These amendments expand the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. On February 1, 2019, the Company has adopted the methodologies prescribed by this ASU and there is no material impact on the Company’s interim condensed consolidated financial statements. |

|  |
| --- |
|   |
| 10 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **2.** | **Significant Accounting Policies** (continued) |
|   |   |   |
|   |   | In July 2017, the FASB issued ASU 2017-11“Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception” (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered, and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common stockholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. On February 1, 2019, the Company adopted ASU 2017-11 with no material impact on the Company’s interim condensed consolidated financial statements. |

|  |  |  |
| --- | --- | --- |
|   | (h) | Accounting Pronouncements Not Yet Adopted |
|   |   |   |
|   |   | In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which modifies certain disclosure requirements related to fair value measurements. ASU 2018-13 will be effective for us beginning February 1, 2020, with early adoption permitted. The Company does not expect this guidance to have an impact on the amounts reported on our consolidated financial statements, and the Company is currently evaluating the potential impact this guidance will have on the disclosures within the notes to the consolidated financial statements. |

|  |  |
| --- | --- |
| **3.** | **Adoption of ASC 842, Leases** |
|   |   |
|   | On February 1, 2019, the Company adopted ASC 842 using the modified retrospective transition approach, which applies the provisions of the new guidance at the effective date without adjusting the comparative periods presented. The cumulative effect of adoption of the lease standard result in change on retained earnings as of February 1, 2019 of $17,802. Results for reporting periods beginning after February 1, 2019 are presented under ASC 842 while prior period amounts are not adjusted and continue to be reported in accordance with the Company’s historic accounting under ASC 840, “Leases”. In accordance with ASC 842, the Company determines if an arrangement is a lease at inception based on whether there is an identified asset, whether the Company has the right to obtain substantially all of the economic benefits from the use of the asset and whether the Company has the right to direct the use of the asset. The Company has operating leases, on office and facility spaces, and no financing leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. See Note 7 for further disclosures and detail regarding the Company’s operating leases. |

|  |
| --- |
|   |
| 11 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **3.** | **Adoption of ASC 842, Leases** (continued) |
|   |   |
|   | For leases with terms greater than twelve (12) months, the Company records the related ROU asset and lease obligation at the present value of lease payments over the term. Leases may include fixed rental escalation clauses, renewal options and / or termination options that are factored into the determination of lease payments when appropriate. The Company’s leases do not provide a readily determinable implicit rate; therefore, an estimate of the Company’s incremental borrowing rate is used to discount the lease payments based on information available at the lease commencement date. The discount rate used was 14.4%. Operating lease costs during the three months ended April 30, 2019 were $136,123 (Note 7). The adoption of ASC 842 resulted in the recognition of right-of-use (“ROU”) assets and lease liabilities of approximately $1,162,218 and $1,180,020, respectively, as of February 1, 2019.   ***Update to Lease Policy*** Accounting and reporting guidance for leases requires that leases be evaluated and classified as either operating or finance leases by the lessee and as either operating, sales-type or direct financing leases by the lessor. The Company’s operating leases are included in ROU assets, lease liabilities - current and lease liability in the condensed consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. |

|  |  |
| --- | --- |
| **4.** | **Asset Acquisitions** |

|  |  |  |
| --- | --- | --- |
|   | (a) | Thrudermic Transdermal Nanotechnology |
|   |   |   |
|   |   | On March 2, 2018, the Company entered into an exchange agreement with Thrudermic, LLC (“Thrudermic”) and the members of Thrudermic whereby the Company paid $1.00 for the issued and outstanding units of Thrudermic and issued 500,000 shares of common stock to the members of Thrudermic for their intellectual property portfolio, including unpatented technology, goodwill and know-how in connection with the Thrudermic Transdermal Nanotechnology. The Company evaluated this acquisition in accordance with ASC 805, Business Combinations to discern whether the assets and operations of Thrudermic met the definition of a business. The Company concluded there were not a sufficient number of key processes obtained to develop the inputs into outputs, nor could such processes be easily obtained by the Company. Accordingly, the Company accounted for this transaction as an asset acquisition at cost of $830,000 (Note 6). |

|  |
| --- |
|   |
| 12 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **4.** | **Asset Acquisitions** (continued) |

|  |  |  |
| --- | --- | --- |
|   | (b) | Ready-to-Infuse Cannabis Patents (“RTIC Patents”) |
|   |   |   |
|   |   | On February 28, 2018, the Company completed the acquisition of Pivot Naturals, LLC (previously ERS Holdings, LLC) (“Pivot Naturals”) pursuant to an exchange agreement dated as of February 10, 2018. As consideration for the purchase, the Company paid $430,420 (US$333,333) in cash on closing, issued 5,000,000 shares of common stock and will pay an additional $430,420 (US$333,333) six (6) and twelve (12) months after closing. Financial consideration include royalties on future annual net sales. On September 28, 2018, a payment of $429,370 (US$326,666), representing a portion of the payment due six (6) months after closing, was made. The Company extended the payment date for the payment due twelve (12) months after closing from February 28, 2019 to May 31, 2019. As consideration for the extension, the Company issued 60,515 shares of common stock (Note 10(c)) and paid $3,358 (US$2,500) in cash, representing the extension fee for March and April 2019, during the three months ended April 30, 2019. The acquisition obligation outstanding as at April 30, 2019 is $456,382 (US$340,000). On May 17, 2019, the last payment due twelve (12) months after closing was made.  The Company evaluated this acquisition in accordance with ASC 805, Business Combinations (10-55-4) to discern whether the assets and operations of Pivot Naturals met the definition of a business. The Company concluded there were not a sufficient number of key processes obtained to develop the inputs into outputs, nor could such processes be easily obtained by the Company. Accordingly, the Company accounted for this transaction as an asset acquisition. The consideration transferred, assets acquired and liabilities assumed recognized is as follows: |

|  |  |  |  |
| --- | --- | --- | --- |
| **Consideration paid:**  |   | $ |   |
|   |   |   |   |
| Cash paid |   |   | 430,420 |   |
| Cash to be paid |   |   | 778,662 |   |
| Common stock issued |   |   | 6,650,000 |   |
| Transaction costs |   |   | 154,951 |   |
|   |   |   |   |   |
| Total purchase price |   |   | 8,014,033 |   |
|   |   |   |   |   |
| **Net assets acquired:**  |   |  | $ |   |
|   |   |   |   |   |
| Cash |   |   | 2,779 |   |
| Equipment |   |   | 5,213 |   |
| Ready-to-infuse cannabis (“RTIC”) patents |   |   | 8,008,411 |   |
| Accounts payable and accrued liabilities |   |   | (2,370 | ) |
|   |   |   |   |   |
| Net value of business purchased |   |   | 8,014,033 |   |

The RTIC patents acquired are amortized over an estimated useful life of ten (10) years.

|  |
| --- |
|   |
| 13 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **5.** | **Equipment** |

|  |  |  |  |
| --- | --- | --- | --- |
| **Cost**  |   | **Lab****Equipment****$** |   |
|   |   |   |   |
| Balance, January 31, 2019 |   |   | 5,307 |   |
| Write-off |   |   | (5,267 | ) |
| Effect of foreign exchange rate changes |   |   | (40 | ) |
|   |   |   |   |   |
| Balance, April 30, 2019 |   |   | - |   |

|  |  |  |  |
| --- | --- | --- | --- |
| **Accumulated Amortization**  |   |   |   |
|   |   |   |   |
| Balance, January 31, 2018 |   |   | 1,145 |   |
| Amortization |   |   | 317 |   |
| Write-off |   |   | (1,366 | ) |
| Effect of foreign exchange rate changes |   |   | (96 | ) |
|   |   |   |   |   |
| Balance, April 30, 2019 |   |   | - |   |
| Net book value, April 30, 2019 |   |   | - |   |
| Net book value, January 31, 2019 |   |   | 4,162 |   |

During the three months ended April 30, 2019, the Company wrote-off its lab equipment and recorded a loss on write-off of equipment of $3,901 (2018 - $nil).

|  |  |
| --- | --- |
| **6.** | **Intangible Assets** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cost**  |   | **BiPhasix****License****$** |   |   | **Thrudermic** **Non-Patented Technology****$** |  |  | **RTIC****Patents****$** |  |  | **Total****$** |  |
|  |  | **(Note 6(a))** |  |  | **(Note 4(a))** |  |  | **(Note 4(b))** |  |  |   |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance, January 31, 2019 |   |   | 319,174 |   |   |   | 830,000 |   |   |   | 8,137,277 |   |   |   | 9,286,451 |   |
| Effect of foreign exchange rate changes |   |   | – |   |   |   | – |   |   |   | 172,725 |   |   |   | 172,725 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance, April 30, 2019 |   |   | 319,174 |   |   |   | 830,000 |   |   |   | 8,310,002 |   |   |   | 9,459,176 |   |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Accumulated Amortization**  |   |   |   |   |   |   |   |   |   |   |   |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance, January 31, 2019 |   |   | 110,618 |   |   |   | 74,325 |   |   |   | 751,686 |   |   |   | 936,629 |   |
| Amortization |   |   | 19,456 |   |   |   | 20,238 |   |   |   | 201,088 |   |   |   | 240,782 |   |
| Effect of foreign exchange rate changes |   |   | – |   |   |   | – |   |   |   | 17,487 |   |   |   | 17,487 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance, April 30, 2019 |   |   | 130,074 |   |   |   | 94,563 |   |   |   | 970,261 |   |   |   | 1,194,898 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net book value, April 30, 2019 |   |   | 189,100 |   |   |   | 735,437 |   |   |   | 7,339,741 |   |   |   | 8,264,278 |   |
| Net book value, January 31, 2019 |   |   | 208,556 |   |   |   | 755,675 |   |   |   | 7,385,591 |   |   |   | 8,349,822 |   |

|  |
| --- |
|   |
| 14 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

Weighted average life remaining on intangible assets is 8.71 years. Future amortization for the next five years is:

|  |  |  |  |
| --- | --- | --- | --- |
| **Expiry Date** |  | **$** |   |
| 2020 |   |   | 751,471 |   |
| 2021 |   |   | 993,794 |   |
| 2022 |   |   | 962,969 |   |
| 2023 |   |   | 914,000 |   |
| 2024 |   |   | 914,000 |   |

|  |  |  |
| --- | --- | --- |
|   | (a) | BiPhasix License |
|   |   |   |
|   |  | On September 12, 2017, the Company entered into a licensing agreement with Altum Pharmaceuticals Inc. (“Altum”), a party related by way of common officer, whereby the Company acquired worldwide rights to the BiPhasix™ transdermal drug delivery technology for the development and commercialization of Cannabinoids, Cannabidiol and Tetrahydrocannabinol products. Consideration included: |

|  |  |  |
| --- | --- | --- |
|   | 1) | Issuance of 2,500,000 shares of common stock on September 12, 2017 valued at $319,174, which was recorded as an intangible asset with a corresponding credit to common stock; |
|   |   |   |
|   | 2) | Issuance of 2,500,000 shares of common stock of Pivot upon Health Canada Natural Product Number approval (not yet issued as of the date of this report); |
|   |   |   |
|   | 3) | Royalties on annual gross sales; and |
|   |   |   |
|   | 4) | For pharmaceutical products, milestone payments payable upon first Investigative New Drug Approval, upon positive outcome of Phase II trial in first indication, and upon New Drug Application approval. As of April 30, 2019 and the date of this report, no milestones have been achieved. |

|  |  |  |
| --- | --- | --- |
|   | (b) | Solumer Oral Drug Delivery Technology |
|   |   |   |
|   |  | On August 7, 2018, the Company entered into a licensing agreement with Formulex Pharma Innovations (formerly Solubest Ltd.) (“Formulex”) whereby the Company will acquire worldwide rights for the use, development and commercialization of Formulex’s Solumer Oral Drug Technology solely for the improved bio-availability, delivery and commercialization of Cannabinoid and Tetrahydrocannabinol-based products for human and animal use. Financial considerations include: 1) Monthly license fee until commercialization date (US$10,000); and 2) Milestone payments upon commercialization (US$150,000) and upon net sales of US$5,000,000 (US$250,000). Other consideration includes royalties on aggregate net sales. In addition, the Company entered into a master formulations services agreement whereby the Company would be Formulex a monthly development fee of US$20,000. During the three months ended April 30, 2019, this master formulations services agreement was terminated. |

|  |
| --- |
|   |
| 15 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **7.** | **Operating Leases** |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **Right-of-use****Asset****$** |  |  | **Lease****Liability****$** |   |
|   |   |   |   |   |   |   |
| Balance, January 31, 2019 |   |   | – |   |   |   | – |   |
| Adoption of ASC 862 (Note 3) |   |   | 1,162,218 |   |   |   | 1,180,020 |   |
| Lease expense |   |   | (92,488 | ) |   |   | – |   |
| Lease liability expense |   |   | – |   |   |   | 47,433 |   |
| Lease payments |   |   | – |   |   |   | (136,123 | ) |
| Effect of foreign exchange rate changes |   |   | 21,418 |   |   |   | 21,678 |   |
|   |   |   |   |   |   |   |   |   |
|   |   |   | 1,091,148 |   |   |   | 1,113,008 |   |
| Current |   |   | – |   |   |   | (249,082 | ) |
| Non-current |   |   | 1,091,148 |   |   |   | 863,926 |   |

The Company is a lessee in two leases that have expiry dates ranging between two (2) and five (5) years. The table below summarizes the remaining expected lease payments under operating leases as of April 30, 2019.

|  |  |  |  |
| --- | --- | --- | --- |
| **Fiscal Years** |   | $ |   |
|   |   |   |   |
| 2020 |   |   | 400,697 |   |
| 2021 |   |   | 339,002 |   |
| 2022 |   |   | 279,938 |   |
| 2023 |   |   | 288,333 |   |
| Thereafter |   |   | 121,612 |   |
| Less: imputed interest  |   |   | (316,574 | ) |
|   |   |   |   |   |
| Present value of operating lease liabilities |   |   | 1,113,008 |   |

|  |  |
| --- | --- |
| **8.** | **Convertible Debenture**  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **April 30,****2019****$** |  |  | **January 31,****2019****$** |   |
|   |   |   |   |   |   |   |
|   |   |   |   |   |   |   |
| March 2, 2018 Convertible Debentures  |   |   | 2,659,375 |   |   |   | 3,497,599 |   |
|   |   |   |   |   |   |   |   |   |
|   |   |   | 2,659,375 |   |   |   | 3,497,599 |   |

On March 2, 2018, the Company issued convertible debentures with two non-related parties totaling $5,000,000. The debentures are secured under a General Security Agreement, bear interest at 10% per annum payable quarterly and mature on March 2, 2019. The notes are convertible into common shares at a conversion price equal to $1.74 per common share. The Company issued 172,413 share purchase warrants with an exercise price of $1.74 and three year expiry as finder’s fee for the convertible debentures. The effective interest rate has been determined as 24% per annum after deducting all the loan discounts.

|  |
| --- |
|   |
| 16 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **8.** | **Convertible Debenture** (continued) |
|   |   |
|   | On October 22, 2018, $1,500,000 of the convertible debentures were settled through the issuance of 3,750,000 units of the Company with each unit consisting of one common stock and one share purchase warrant with an exercise price of $0.60 and three year expiry. The shares issued were valued at $0.43 per share and warrants issued were valued at $0.26 per warrant for total value of $2,600,856. The fair value of warrants were calculated using volatility of 110%, interest-free rate of 2.30%, nil expected dividend yield and expected life of 3 years. The Company considered the settlement to be an extinguishment of the $1,500,000 of the convertible debentures. On October 22, 2018, the Company modified the conversion price on the remainder of the convertible debentures, totaling $3,500,000, to $0.42 per common share. The Company considered the modification to be an extinguishment of the $3,500,000 of the convertible debentures. The effective interest rate for the remaining terms of the convertible debentures has been determined as 21% per annum. On March 2, 2019, the Company repaid $750,000 of the convertible debentures and extended the maturity of the remainder of the convertible debentures to June 2, 2019 for an extension fee of $250,000. The Company considered the extension to be a modification of the convertible debentures. The effective interest rate for the remaining terms of the convertible debentures has been determined as 39% per annum. During the three months ended April 30, 2019, interest expense for the three months ended April 30, 2019 was $131,582.  As of April 30, 2019, the carrying value of the convertible debentures is $2,659,375 (January 31, 2019 - $3,497,599) and interest payable on the convertible debentures is $nil (January 31, 2019 - $30,194). Please also refer to Note 17(c). |

|  |  |
| --- | --- |
| **9.** | **Promissory Note** |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **April 30,****2019****$** |  |  | **January 31,****2019****$** |   |
|   |   |   |   |   |   |   |
| Principal (Note 9(c)) |   |   | 270,666 |   |   |   | - |   |
|   |   |   |   |   |   |   |   |   |
|   |   |   | 270,666 |   |   |   | - |   |

|  |  |  |
| --- | --- | --- |
|   | (a) | Promissory Note – Former Chief Executive Officer |
|   |   |   |
|   |  | In September 2017, the Company issued a promissory note bearing interest at 8% per annum. Principal and accrued interest are due on the earlier of: 1) 30 days after the completion of a financing of at least US$2,000,000 and (ii) September 10, 2027, provided that if repayment occurs prior to the second anniversary date, all interest will be waived. On March 2, 2018, the Company issued senior secured convertible debentures for gross proceeds of $5,000,000 (Note 8). Accordingly, accrued interest being waived, principal was due and repaid on March 30, 2018. A gain on repayment of promissory note of $8,890 was recorded during the three months ended April 30, 2018. |

|  |
| --- |
|   |
| 17 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **9.**  | **Promissory Note** (continued) |
|   |   |   |
|   | (b) | Promissory Note – Altum Pharmaceuticals Inc. (“Altum”) |
|   |   |   |
|   |  | On February 16, 2018, the Company issued a promissory note of up to $520,000, bearing interest at 10% per annum to Altum and maturing on May 15, 2018. On February 19 and March 1, 2018, $250,000 and $252,464 were advanced to the Company. On March 2, 2018, the Company repaid the principal amount and accrued interest on the promissory note totaling $503,285. |
|   |   |   |
|   | (c) | Promissory Note – Third Party |
|   |   |   |
|   |   | On March 5, 2019, the Company issued a promissory note of $300,000, bearing interest at 10% per annum and maturing on September 5, 2019. Pursuant to the issuance of this promissory note, the Company issued 100,000 shares of common stock as a loan origination fee (Note 10(a)) and incurred cash finders’ fee of $24,000.  |
|   |   |   |
|   |   | Interest expense for the three months ended April 30, 2019 was $19,274 (2018-$nil).  As of April 30, 2019, the carrying value of the promissory note is $270,666 (January 31, 2019 - $nil) and interest payable on the promissory note is $4,607 (January 31, 2019 - $nil). |

|  |  |
| --- | --- |
| **10.**  | **Common Stock** |
|   |   |   |
|   | (a) | On March 5, 2019, the Company issued 100,000 shares of common stock to a third party as a loan origination fee (Note 9(c)). |
|   |   |   |
|   | (b) | On March 23, 2019, the Company issued 1,035,714 to third parties for services provided. On the same date, the Company issued 690,323 shares of common stock to directors and officers to settle outstanding compensation (Notes 14(b), (c) and (d)). |
|   |   |   |
|   | (c) | On April 8, 2019, the Company issued 60,515 shares of common stock as an extension fee for an outstanding obligation (Note 4(b)). |
|   |   |   |
|   | (d) | On April 8, 2019, a private placement was closed for an aggregate of 6,950,000 units, consisting of one common share and one share purchase warrant, at price of $0.20 per unit, for gross proceeds of $1,390,000. $60,000 of the gross proceeds, relating to 300,000 units, was received by the Company subsequent to April 30, 2019 (Note 17(a)). Each share purchase warrant entitles the holder to purchase one common share at a price of $0.30 per share and has an expiry term of three (3) years. Finders’ fees consisted of cash payments of $80,000 and issuance of 508,000 shares of common stock and 108,000 share purchase warrants entitling the holders to purchase one common share at a price of $0.30 per share and has an expiry term of three (3) years. |
|   |   |   |
| **11.**  | **Stock Options** |
|   |   |   |
|  | Effective December 30, 2015, the Company adopted a stock option plan. Under this plan, the Company may grant options to its directors, officers, employees and consultants up to an amount as determined by the Company and will be no more than a percentage of its outstanding common stock as may be required by the stock exchange the Company is listed with. The exercise price of the stock options will be determined by the Company and will be no less than any minimum exercise price as may be required by the stock exchange the Company is listed with. |

|  |
| --- |
|   |
| 18 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **11.** | **Stock Options** (continued) |
|   |   |
|   | The following table summarizes the continuity of the Company’s stock options: |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |   | **Number** **of Options****#** |  |  | **Weighted** **Average** **Exercise** **Price****$** |  |  | **Weighted** **Average** **Remaining Contractual Life (Years)** |   |
|   |   |   |   |   |   |   |   |   |   |
| Outstanding, January 31, 2019 |   |   | 13,691,833 |   |   |   | 0.48 |   |   |   | 2.31 |   |
| Granted |   |   | – |   |   |   | – |   |   |   | – |   |
| Forfeited |   |   | (41,833 | ) |   |   | 0.07 |   |   |   | – |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
| Outstanding, April 30, 2019  |   |   | 13,650,000 |   |   |   | 0.48 |   |   |   | 2.06 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
| Exercisable, April 30, 2019  |   |   | 13,650,000 |   |   |   | 0.48 |   |   |   | 2.06 |   |

The aggregate intrinsic value of vested options outstanding at April 30, 2019 is $2,454,755. Additional information regarding stock options as of April 30, 2019, is as follows:

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Options Outstanding** |  |  | **Options** **Exercisable** |  |  | **Exercise****Price****$** |  |  | **Expiry** **Date** |   |
|   | 4,000,000 |   |   |   | 4,000,000 |   |   |   | 0.14 |   |   | December 14, 2020 |   |
|   | 5,250,000 |   |   |   | 5,250,000 |   |   |   | 0.97 |   |   | February 22, 2021 |   |
|   | 4,000,000 |   |   |   | 4,000,000 |   |   |   | 0.13 |   |   | December 14, 2021 |   |
|   | 100,000 |   |   |   | 75,000 |   |   |   | 0.50 |   |   | November 14, 2022 |   |
|   | 200,000 |   |   |   | 200,000 |   |   |   | 1.67 |   |   | March 11, 2023 |   |
|   | 100,000 |   |   |   | 100,000 |   |   |   | 0.42 |   |   | October 28, 2023 |   |
|   | 13,650,000 |   |   |   | 13,625,000 |   |   |   |   |   |   |   |   |

|  |  |
| --- | --- |
|   | $5,896 (2018 – $34,898) of stock-based compensation expense has been recognized during the three months ended April 30, 2019. $Nil (2018 - $62,794) of stock-based compensation cost has yet to be recognized and will be recognized in future periods. |
|   |   |
| **12.** | **Share Purchase Warrant** |
|   |   |
|   | The following table summarizes the continuity of share purchase warrant: |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **Number of****Warrants** |  |  | **Weighted** **Average** **Exercise Price****$** |   |
|   |   |   |   |   |   |   |
| Balance, January 31, 2019  |   |   | 8,486,048 |   |   |   | 0.62 |   |
| Granted (Note 10(d)) |   |   | 6,758,000 |   |   |   | 0.30 |   |
| Balance, April 30, 2019 |   |   | 15,244,048 |   |   |   | 0.48 |   |

As at April 30, 2019, the following share purchase warrants were outstanding:

|  |
| --- |
|   |
| 19 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **12.** | **Share Purchase Warrant** (continued) |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Number of Warrants**  |  |  | **Exercise****Price****$** |  |  | **Expiry** **Date** |  | **Weighted** **Average****Remaining Contractual****Life (Years)** |   |
|  |   |   |   |   |   |   |   |   |   |   |
|   | 190,000 |   |   |   | 0.45 |   |   | May 20, 2019 |   |   | 0.05 |   |
|   | 75,125 |   |   |   | 0.45 |   |   | June 14, 2019 |   |   | 0.12 |   |
|   | 172,413 |   |   |   | 1.74 |   |   | March 1, 2021 |   |   | 1.84 |   |
|   | 3,353,250 |   |   |   | 0.60 |   |   | September 21, 2021 |   |   | 2.40 |   |
|   | 8,000 |   |   |   | 0.60 |   |   | October 1, 2021 |   |   | 2.42 |   |
|   | 907,260 |   |   |   | 0.60 |   |   | October 18, 2021 |   |   | 2.47 |   |
|   | 3,780,000 |   |   |   | 0.60 |   |   | October 22, 2021 |   |   | 2.48 |   |
|   | 6,758,000 |   |   |   | 0.30 |   |   | March 16, 2022 |   |   | 2.88 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
|   | 15,244,048 |   |   |   |   |   |   |   |   |   | 2.59 |   |

|  |  |
| --- | --- |
| **13.** | **Supplemental Cash Flow Information** |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **Three Months****Ended****April 30,****2019****$** |  |  | **Three Months****Ended****April 30,****2018****$** |   |
| Supplemental disclosures: |   |   |   |   |   |   |
| Interest paid |   |   | 65,124 |   |   |   | 41,096 |   |
| Income tax paid |   |   | – |   |   |   | – |   |
| Non-cash investing and financing activities |   |   |   |   |   |   |   |   |
| Stock issued for services (Note 10(c)) |   |   | 64,315 |   |   |   | 227,587 |   |
| Stock issuable for services |   |   | – |   |   |   | 64,265 |   |
| Stock issued for settlement of accounts payable (Note 10(b)) |   |   | 338,064 |   |   |   | – |   |
| Stock issued for loan origination fees (Note 10(a)) |   |   | 20,000 |   |   |   | – |   |
| Stock issued for intangible assets (Note 4(a)) |   |   | – |   |   |   | 830,000 |   |
| Stock issued for acquisition of business (Note 4(b)) |   |   | – |   |   |   | 6,650,000 |   |
| Stock issued for finder’s fee (Note 10(d)) |   |   | 127,000 |   |   |   | – |   |
| Warrants granted for finder’s fee (Note 10(d)) |   |   | 19,804 |   |   |   | 262,400 |   |

|  |  |
| --- | --- |
| **14.**  | **Related Party Transactions** |
|   |   |   |
|   | (a) | As at April 30, 2019, the Company owed $40,682 (January 31, 2019 - $63,335) to its Chief Executive Officer and director. These amounts are unsecured, non-interest bearing, and due on demand. During the three months ended April 30, 2019, the Company recorded a salary of $50,000 (2018 - $50,000) to its Chief Executive Officer and director. |
|   |   |   |
|   | (b) | As at April 30, 2019, the Company owed $26,575 (January 31, 2019 - $38,248) to its Chief Financial Officer. These amounts are unsecured, non-interest bearing, and due on demand. During the three months ended April 30, 2019, the Company recorded a salary of $40,000 (2018 - $30,000) to its Chief Financial Officer. The Company also issued 200,000 shares of common stock to settle outstanding obligations to its Chief Financial Officer for the payroll expenses from October through December 2018.  |

|  |
| --- |
|   |
| 20 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **14.**  | **Related Party Transactions (continued)** |
|   |   |   |
|   | (c) | As at April 30, 2019, the Company owed $13,622 (January 31, 2019 - $12,702) to its Vice President, Technology and director. These amounts are unsecured, non-interest bearing, and due on demand. During the three months ended April 30, 2019, the Company recorded a salary of $68,258 (2018 - $23,847) to its Vice President, Technology and director. The Company also issued 290,323 shares of common stock to settle outstanding obligations to its Vice President, Technology and director for January through March 2019. |
|   |   |   |
|   | (d) | As at April 30, 2019, the Company owed $10,798 (January 31, 2019 - $23,811) to a director. These amounts are unsecured, non-interest bearing, and due on demand. During the three months ended April 30, 2019, the Company recorded a fee, included in salary and wages, of $25,000 (2018 - $nil) to its director. The Company also issued 200,000 shares of common stock to settle outstanding obligations to its director for October 2018 through March 2019. |
|   |   |   |
|   | (e) | On September 12, 2017, the Company entered into a licensing agreement with Altum, a party related by way of common officer, whereby the Company acquired worldwide rights to the BiPhasix™ transdermal drug delivery technology for the development and commercialization of Cannabinoids, Cannabidiol and Tetrahydrocannabinol products (Note 6(a)). As at January 31, 2019, the Company owed Altum $112,351 (January 31, 2019 - $48,896) for expenses paid on behalf of the Company. These amounts are unsecured, bear interest at 10% per annum, and due on demand. In May 2019, the Company repaid, in full, the outstanding due to Altum plus accrued interest. |
|   |   |   |
|   | (f) | As at April 30, 2019, the Company owed $81,488 (January 31, 2019 - $50,209) to Chief Business Officer. These amounts are unsecured, non-interest bearing, and due on demand. During the three months ended April 30, 2019, the Company recorded a fee, included in salary and wages, of $50,000 (2018 - $50,000) to its Chief Business Officer. |
|   |   |   |
|   | (g) | During the three months ended April 30, 2019, the Company’s subsidiary, Pivot Naturals, owed $229,492(January 31, 2019 - $93,282) to its former President and a company owned by the former President. These amounts are unsecured, non-interest bearing, and due on demand. During the three months ended April 30, 2019, Pivot Naturals recorded a salary of $133,210 (2018 - $56,271) to its former President. |
|   |   |   |
| **15.**  | **Joint Venture** |
|   |   |
|   | On December 17, 2018, the Company entered into a joint venture arrangement whereby the Company holds 50% of the issued and outstanding shares of Pivot-Cartagena JV. Pivot-Cartagena JV will develop and commercialize cannabis-infused non-alcoholic beverages using the industry expertise of its joint venture partner with the Company’s Solumer (Note 6(b)) and RTIC (Note 4(b)) powderization technologies. The Company and its joint venture partner each have 50% to the net assets and net income or loss of Pivot-Cartagena JV. As of April 30, 2019, the Company has not made any investment related to Pivot-Cartagena JV. During the three months ended April 30, 2019, there were no balances or transactions related to Pivot-Cartagena JV. |

|  |
| --- |
|   |
| 21 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Period ended April 30, 2019

(Expressed in Canadian dollars)

|  |  |
| --- | --- |
| **16.** | **Commitments and Contingencies** |
|   |   |
|   | In April 2019, the employment of two of the Company’s employees in Pivot Naturals, including the President of Pivot Naturals, which was pursuant to written employment contracts, terminated. A demand for arbitration has been made by these former employees along with a draft arbitration complaint that alleges claims for breach of the written employment contracts, fraud, illegal retaliation and tortious discharge in violation of public policy seeking, among other things, recovery of accrued and unpaid salary and wages in the total amount of $213,179 and contractual severance amounts totaling US$475,000 alleged to be due and owing on their alleged involuntary termination, as well as other general and punitive damages. The Company intends to vigorously defend these claims and file cross-claims against the former employees for breach of contract and related tort claims. The Company has not accrued contractual severance amounts totaling US$475,000 as of April 30, 2019 as management is not able to assess the likelihood of payment. The unpaid salary and wages were accrued as of April 30, 2019. In June 2019, the Company paid all accrued and unpaid salary and wages to these former employees.  |
|   |   |
| **17.**  | **Subsequent Events** |

|  |  |  |
| --- | --- | --- |
|   | (a) | Subsequent to April 30, 2019, the Company received $60,000, representing the outstanding gross proceeds related to the private placement disclosed in Note 10(d). |
|   |   |   |
|   | (b) | On May 15, 2019, the Company closed the first tranche of a private placement for an aggregate of 46,132,000 units, consisting of one common share and one share purchase warrant, at price of $0.25 per unit, for gross proceeds of $11,533,000. On May 30, 2019, the Company closed the last tranche of a private placement for an aggregate of 13,868,000 units, consisting of one common share and one share purchase warrant, at price of $0.25 per unit, for gross proceeds of $3,467,000. Each share purchase warrant entitles the holder to purchase one common share at a price of $0.35 per share and has an expiry term of two (2) years. Pursuant to the private placement, the Company issued 4,200,000 units, consisting of one common share and one share purchase warrant, representing 7% of the total units issued in the private placement as advisory fees. Each share purchase warrant entitles the holder to purchase one common share at a price of $0.35 per share and has an expiry term of two (2) years. |
|   |   |   |
|   | (c) | Subsequent to April 30, 2019, the Company extinguished, in full, convertible debentures totaling $2.75 million through the issuance of 595,238 common shares pursuant to the conversion of $250,000 of the convertible debentures and the repayment of the remaining $2.5 million in cash. |
|   |   |   |
|   | (d) | Subsequent to April 30, 2019, the Company placed an initial production order for 100,000 units of micellized CBD Solution with SolMic GmbH (“Solmic”). In connection with the production order, the Company made an up-front payment of EUR953,400 to Solmic. |
|   |   |   |
|   | (e) | Effective June 12, 2019, the Company cancelled 700,000 options to purchase common shares at an exercise price of US$0.70 and expiring on February 22, 2021. The Company also granted 2,700,000 options to purchase common shares at an exercise price of $0.40 and expiring on June 11, 2024. |

|  |
| --- |
|   |
| 22 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

Forward-Looking Statements

This report on Form 10-Q contains certain forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of these provisions, including any projections of earnings, revenues, or other financial items; any statements of the plans, strategies, and objectives of management for future operation; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; statements of belief; and any statement of assumptions underlying any of the foregoing. Such forward-looking statements are subject to inherent risks and uncertainties, and actual results could differ materially from those anticipated by the forward-looking statements.

These forward-looking statements involve significant risks and uncertainties, including, but not limited to, the following: competition, promotional costs and the risk of declining revenues. Our actual results could differ materially from those anticipated in such forward-looking statements as a result of a number of factors. These forward-looking statements are made as of the date of this filing, and we assume no obligation to update such forward-looking statements. The following discusses our financial condition and results of operations based upon our unaudited financial statements which have been prepared in conformity with accounting principles generally accepted in the United States. It should be read in conjunction with our financial statements and the notes thereto included elsewhere herein.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are stated in Canadian Dollars (C$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in Canadian Dollars (C$) and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our” and “our company” mean Pivot Pharmaceuticals Inc., unless otherwise indicated.

***General Overview***

We are an early stage pharmaceutical company. We were incorporated in the Province of British Columbia, Canada under the name “649186 B.C. Ltd.”, on June 10, 2002. On September 9, 2003, we changed our name to “Xerxes Health Corp.” and on June 26, 2007, we changed our name to “Neurokine Pharmaceuticals Inc.”.

Effective June 4, 2014, we filed with the British Columbia Registrar of Companies a Form 11, Notice of Alteration, wherein we increased our authorized share capital from 500,000,000 common shares without par value to an unlimited number of common shares without par value. The increase of authorized capital was approved by our stockholders at the annual and special meeting held on June 3, 2014.

On September 26, 2014, our company held a special meeting of stockholders to approve the removal of our company's Pre-Existing Company Provisions, the cancellation of our current Articles and the adoption of new Articles and to approve a reverse stock split on the basis of up to one new common stock for every 100 old common stock.

|  |
| --- |
|   |
| 23 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

Effective October 8, 2014, we filed with the British Columbia Registrar of Companies a Form 11, Notice of Alteration, wherein we removed our Pre-Existing Company Provisions.

Effective April 7, 2015, we filed with the British Columbia Registrar of Companies a Form 11, Notice of Alteration, wherein we changed our name to "Pivot Pharmaceuticals Inc.".

Effective at the opening of trading on April 20, 2015, as approved by FINRA, our company effected a reverse stock split of our issued and outstanding common shares on the basis of 10 old common stock for 1 new common stock.

On November 20, 2015, we completed the acquisition of IndUS Pharmaceuticals, Inc. (“IndUS”), a Delaware corporation, pursuant to an Agreement and Plan of Merger and Acquisition Agreement dated as of November 4, 2015 among our company, Pivot Pharma U.S. Inc., our wholly owned subsidiary, IndUS and Sindu Research Laboratories Pvt Ltd. As consideration for the purchase, we issued 4,512,500 shares of common stock on November 23, 2015 and 237,500 shares of common stock on December 4, 2015 and granted 41,833 stock options pursuant to the Agreement and Plan of Merger. As part of the acquisition, we appointed Dr. Pravin Chaturvedi as our new Chief Executive Officer and Director. On September 11, 2017, we completed an exchange agreement whereby we exchanged with Dr. Chaturvedi 100% of its shares of common stock of IndUS and IndUS net liabilities for 3,800,000 shares of common stock of Pivot, upon which Dr. Chaturvedi resigned as Chief Executive Officer and Director.

On September 12, 2017, we entered into a licensing agreement with Altum Pharmaceuticals Inc. (“Altum”) whereby we were granted worldwide rights to BiPhasix Transdermal Drug Delivery Technology (“BiPhasix Technology”) for the delivery and commercialization of cannabinoids, cannabidiol (“CBD”), and tetrahydrocannabinol (“THC”) based products. Financial consideration included:

|  |  |  |
| --- | --- | --- |
|   |  | Issuance of 2,500,000 shares of common stock on effective date of agreement |
|   |  | Issuance of 2,500,000 shares of common stock of Pivot upon Health Canada Natural Product Number (“NPN”) approval; |
|   |  | Royalties on annual gross sales; and |
|   |  | For pharmaceutical products, milestone payments payable upon first Investigative New Drug Approval, upon positive outcome of Phase II trial in first indication, and upon New Drug Application approval. |

On December 19, 2017, we commenced trading on the Canadian Securities Exchange under the symbol "PVOT".

On February 28, 2018, we completed the acquisition of Pivot Naturals, LLC (previously ERS Holdings, LLC) (“Pivot Naturals”) pursuant to an Exchange Agreement dated as of February 10, 2018 among Pivot Pharmaceuticals Inc. ("Pivot"), Pivot Naturals and the members of Pivot Naturals. As consideration for the purchase, we paid US$333,333 in cash on closing and will pay an additional US$333,333 six (6) and twelve (12) months after closing for total cash payment of US$1 million. The payment due six (6) months after closing was paid in September 2018. The payment due twelve (12) months after closing has been extended to May 31, 2019 for an extension fee of 2.5% per month payable in cash and/or shares of common stock. In addition, we also issued 5,000,000 shares of our common stock and will pay royalties on future net sales. Pivot Naturals has developed a patented technology called “RTIC” Ready-To-Infuse-Cannabis, relating to the transformation of cannabis oil into powder for infusion into a variety of food and beverage products such as capsules, K-Cups, stick packs, baked mixes, liquid shots, protein shakes, topicals, lotions, and bottled beverages.

On March 2, 2018, we completed the acquisition of Thrudermic, LLC (“Thrudermic”) and worldwide rights to Thrudermic’s patented Transdermal Nanotechnology for the development and commercialization of transdermal cannabinoids pursuant to an Exchange Agreement dated as of March 2, 2018 among Pivot, Dr. Joseph Borovsky, Dr. Leonid Lurya and Thrudermic. As consideration for the purchase, we paid $1 in cash on closing and issued 500,000 shares of our common stock.

|  |
| --- |
|   |
| 24 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

On August 7, 2018, we entered into a licensing agreement with Formulex Pharma Innovations (formerly Solubest Ltd.) (“Formulex”) whereby we acquired worldwide rights for the use, development and commercialization of its patented Solumer™ Oral Drug Delivery Technology ("Solumer™") for the improved bioavailability, delivery and commercialization of CBD, THC and other biocannabis-based products. Financial consideration included:

|  |  |  |
| --- | --- | --- |
|   |  | Royalties on net sales; |
|   |  | Monthly license fee from execution of the agreement until commercialization; and |
|   |  | Milestone payments upon commercialization and aggregate net sales of $5,000,000. |

On December 17, 2018, we entered into a joint venture arrangement whereby we hold 50% of the issued and outstanding shares of Pivot-Cartagena Joint Venture Inc. (“Pivot-Cartagena JV”). Pivot-Cartagena JV will develop and commercialize cannabis-infused non-alcoholic beverages combining the industry expertise of Licorera del Sur with our patented Solumer™ and RTIC™ powderization technologies.

Our principal executive office is located at 1275 West 6th Avenue, Vancouver, B.C. Canada V6H 1A6. Our telephone number is (514) 943-1899.

***Our Current Business***

We are a bio-cannabis consumer products company engaged in the commercialization of patented, science-based, premium health and wellness products. We have invested in the acquisition and licensing of patented drug delivery technologies and have developed and tested differentiated cannabis formulations using pharmaceutical grade CBD and THC isolates as active ingredients. Working with our network of pharmaceutical product experts, we have created a catalogue of bioavailable, stable cannabis products. Our products will be manufactured at current Good Manufacturing Practices (“GMP”) accredited facilities in Canada, California, Vermont and Germany. Our products will initially be marketed under our “Pivot Naturals” brand and distributed globally through established wholesale, retail, e-commerce and government partners.

Our premium branded product line includes tablets, capsules and soft gels, bulk powder, stick packs, infused beverages, oral solutions, lotions, creams, gels, gums, mints, candies, intimate lubricant and pet supplements.

Our strategic priorities are to:

|  |  |  |
| --- | --- | --- |
|   | 1. | Continue to build our industry leading portfolio of patented drug delivery technologies; |
|   | 2. | Commercialize our bio-cannabis product lines; |
|   | 3. | Secure global distribution channels for our product lines; and |
|   | 4. | Establish partnerships with large and specialty pharmaceutical companies and/or biotechnology companies to collaboratively develop and/or commercialize certain products in our portfolio. |

***Our Research and Development Strategy***

Our management team has implemented a business-minded and cost-conscious approach to product research and development by focusing on development of bio-cannabis nutraceuticals and selling the finished products into markets where regulations permit. We will use contract development and manufacturing organizations on a fee for service basis to perform any research or development that is required.

***Our Platform Technologies***

BiPhasix Transdermal Drug Delivery Technology (Topical Platform)

We have acquired worldwide rights from Altum Pharmaceuticals Inc. for its patented topical transdermal drug delivery technology platform, or BiPhasix, which we will use for the delivery and commercialization of cannabinoid, CBD and THC-based products. The BiPhasix technology has the potential to deliver drugs less invasively than by injections. It also has the potential to topically deliver therapeutic amounts of drugs with better absorption rates, where creams, ointments or conventional liposomes have not been effective.

|  |
| --- |
|   |
| 25 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

Thrudermic Transdermal Nanotechnology (Topical Platform)

We have acquired the worldwide rights to Thrudermic’s patented Transdermal Nanotechnology for the development and commercialization of transdermal cannabinoids. Developed in Israel, the Thrudermic lipid-based nano dispersion technology for topical cannabinoids uses FDA approved materials. The technology has the ability to specifically formulate individual drugs to control and prolong drug release while maintaining steady therapeutic concentrations, The technology can handle water soluble and water insoluble drugs with no change to the skin morphology, no sensitivity to the digestive system, no pain from injections and no observed adverse reactions.

Solmic Solubilization Drug Delivery Technology (Oral Platform)

We will enter into purchase agreements with Solmic GmbH (“Solmic”) for the purchase of Solmic’s oral 1% Micelle solution. Subject to meeting annual minimum order quantities, we will receive worldwide exclusive rights to this product, made with patented Micelle technology.

Solumer Drug Delivery Technology (Oral Platform)

We have acquired the worldwide rights to Formulex’s Solumer Technology for the oral delivery of cannabinoids, such as CBD and THC, with improved bioavailability. The Solumer Technology allows to convert the cannabinoids to powder for tablets and capsules and the powder can be dispersed in liquids to give a clear solution that is colorless, and flavorless for beverage applications.

Ready-To-Infuse Cannabis Technology

Pivot’s patented Ready-To-Infuse-Cannabis (“RTIC”) process technology creates precise and repeatable dosing of cannabis by transforming concentrated cannabis oil into a stable, emulsifiable, odorless and flavorless powder form. The derived powder may then be encapsulated and infused for use in beverages, edibles, lotions and additional health and personal care products. The RTIC process is conducive for manufacturing of a wide array of products.

***Our Product Development Initiatives***

In addition to our bio-cannabis nutraceutical product pipeline, we have the opportunity develop a pharmaceutical pipeline in the future, financing permitting.

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | **DELIVERY TECHNOLOGY** | **INDICATION** | **GLOBAL MARKET SIZE (1)** |
| PGS-N001 | Solmic Solubilisate / Oral or RTIC/Solumer Tablet | Cancer supportive care (CINV) (chemo-induced nausea and vomiting) | >$1B |
| PGS-N002 | Solmic Solubilisate / Oral | Restless leg syndrome | >$2B |
| PGS-N003 | Solmic Solubilisate / Oral or RTIC/Solumer Tablet | Pain and inflammation (for opioid withdrawal) | >$15B |
| PGS-N004 | Solmic Solubilisate / Oral | Cancer supportive care (mucositis relief) | >$12B |
| PGS-N005 | BiPhasix/Thrudermic / Topical | Female sexual dysfunction (HSDD) (hypoactive sexual desire disorder) | >$6B |
| PGS-N006 | BiPhasix/Thrudermic / Topical | Pain and inflammation (joints/opioid withdrawal) | >$20B |
| PGS-N007 | BiPhasix/Thrudermic / Topical | Dermatology (skin irritation/redness/ itching) | >$13B |
| PGS-N008 | BiPhasix/Thrudermic / Topical | Eye disease (glaucoma, intra-ocular pressure) | >$3B |
| PGS-N009 | Thrudermic / Topical | Pain and inflammation (opioid withdrawal) | >$15B |
| PGS-N010 | Solmic Solubilisate / Oral or RTIC/Solumer | Migraine (nausea, vomiting, dizziness, sensitivity to light, sounds and smells) | >$10B |

\_\_\_\_\_\_\_\_\_\_\_

(1) Derived from IMS data

|  |
| --- |
|   |
| 26 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

We have no plans to initiate any clinical trials of our pharmaceutical pipeline at this time.

***Results of Operations***

The following summary of our results of operations should be read in conjunction with our financial statements for the period ended April 30, 2019, which are included herein.

Our operating results for the three months ended April 30, 2019 and 2018 are summarized as follows:

|  |  |  |  |
| --- | --- | --- | --- |
|   |   | **Three Months Ended**  |   |
|   |   | **April 30,** |   |
|   |   | **2019** |   |   | **2018** |   |
| Revenue  |   | $ | Nil |   |   | $ | Nil |   |
| Amortization  |   | $ | (241,099 | ) |   | $ | (165,613 | ) |
| Due diligence costs |   | $ | Nil |   |   | $ | (122,672 | ) |
| Foreign exchange gain (loss)  |   | $ | 16,825 |   |   | $ | (49,249 | ) |
| General and administrative  |   | $ | (506,786 | ) |   | $ | (955,954 | ) |
| Lease expense |   | $ | (92,488 | ) |   | $ | Nil |   |
| Lease liability expense |   | $ | (47,433 | ) |   | $ | Nil |   |
| Licensing fees |   | $ | (39,963 | ) |   | $ | Nil |   |
| Professional fees  |   | $ | (181,649 | ) |   | $ | (226,169 | ) |
| Research and development |   | $ | (59,487 | ) |   | $ | (108,801 | ) |
| Salaries and wages |   | $ | (505,056 | ) |   | $ | (240,514 | ) |
| Sales and marketing |   | $ | Nil |   |   | $ | (8,929 | ) |
| Write-off of equipment |   | $ | (3,901 | ) |   | $ | Nil |   |
| Total Other Income (Expenses) |   | $ | (213,086 | ) |   | $ | (226,975 | ) |
| Net Income (Loss)  |   | $ | (1,874,123 | ) |   | $ | (2,104,876 | ) |

For the three months ended April 30, 2019, our net loss decreased by $230,753. Net loss decreased primarily from decreases in due diligence costs, general and administrative, professional fees and research and development, offset by increases amortization, licensing fees, rent and salaries and wages. During the three months ended April 30, 2018, we completed the acquisitions of the Thrudermic Transdermal Nanotechnology and Pivot Naturals, LLC (formerly ERS Holdings, LLC) and its RTIC patents, which increased due diligence costs, consulting fees within general and administrative costs, professional fees and research and development. Research and development work performed during the three months ended April 30, 2018 included development of CBD topical and oral formulations, including permeability studies. During the three months ended April 30, 2019, we conducted animal dermal studies using CBD formulations developed.

Increases in expenses during the three months ended April 30, 2019 were due to the following. For the 2019 quarter, we paid licensing fees to Formulex pursuant to a licensing agreement on the Solumer technology entered into in August 2018. We also made lease payments on our facilities in Quebec, Canada and California, USA, both of which were entered into in July 2018. Salaries and wages increased by $264,542 for the three months ended April 30, 2019. For the three months ended April 30, 2018, salaries paid on employment contracts entered into pursuant to the acquisitions of Thrudermic and RTIC patents began in March 2018 and were not paid for the full interim period. Salaries and wages were higher for the three months ended April 30, 2019 due to the following: 1) We paid salaries to two (2) additional administrative staff in Pivot Naturals, who were hired in June 2018, and 2) Pursuant to the termination of three (3) employees in Pivot Naturals, California wage penalties of approximately $56,100 were incurred.

|  |
| --- |
|   |
| 27 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

Revenue

We have not earned any revenues since our inception. We anticipate earning revenues from sales of micellized CBD Solutions beginning the second or third quarter of fiscal 2020.

***Liquidity and Financial Condition***

Working Capital

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **At**  |   |   | **At**  |   |
|   |   | **April 30,**  |   |   | **January 31,**  |   |
|   |   | **2019** |   |   | **2019** |   |
| Current Assets  |   | $ | 193,847 |   |   | $ | 241,874 |   |
| Current Liabilities  |   | $ | 5,316,836 |   |   | $ | 5,086,227 |   |
| Working Capital (Deficit)  |   | $ | (5,122,989 | ) |   | $ | (4,844,353 | ) |

Our total current assets as of April 30, 2019 were $193,847 as compared to $241,874 as of January 31, 2019. We received gross proceeds of $1,250,000 from issuance of units, consisting of a common stock and a share purchase warrant, and $300,000 from a promissory note. These proceeds were used to repay $750,000 of our outstanding convertible debentures, as well as extend the remaining maturity of the convertible debentures to June 2, 2019 for an extension fee of $250,000. The remainder of the proceeds, plus cash on hand from January 31, 2019, were used to fund key working capital requirements, resulting in an overall decrease in cash. Current liabilities increased from January 31, 2019 due primarily to the issuance of a promissory note totaling $300,000, recording of a current lease liability of $249,082 pursuant to the adoption of a new accounting standard, ASC 872 Leases, and continuing accruals from services provided by our service providers during the quarter. This increase was offset by the repayment of $750,000 of our convertible debentures.

Cash Flows

|  |  |  |  |
| --- | --- | --- | --- |
|   |   | **Three Months Ended**  |   |
|   |   | **April 30,** |   |
|   |   | **2019** |   |   | **2018** |   |
| Net Cash Used In Operating Activities  |   | $ | (567,811 | ) |   | $ | (2,419,215 | ) |
| Net Cash Used In Investing Activities |   | $ | Nil |   |   | $ | (426,159 | ) |
| Net Cash Provided By Financing Activities  |   | $ | 526,000 |   |   | $ | 4,676,745 |   |
| Effects of Exchange Rate Changes on Cash |   | $ | 12,425 |   |   | $ | 13,113 |   |
| **Increase (Decrease) in Cash During the Period**  |   | **$** | **(29,386** | **)** |   | **$** | **1,844,484** |  |

*Operating Activities*

During the three months ended April 30, 2019, our cash used by operating activities decreased by $1,851,404 when compared to cash used in operating activities during the three months ended April 30, 2019. During the prior period, proceeds from convertible debentures issued during the period allowed our company to pursue our business strategy, including development of our oral and transdermal drug delivery platforms and preparation of our RTIC products for production and commercialization, which resulted in increased research and development costs and salaries and wages. Also, during prior period, we acquired Pivot Naturals and the Thrudermic Transdermal Nanotechnology, which resulted in increase in other operating activities, such as due diligence, general and administrative, professional services.

|  |
| --- |
|   |
| 28 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

*Investing Activities*

During the three months ended April 30, 2018, we acquired Pivot Naturals through the issuance of 5,000,000 shares of our common stock and a payment of $428,438 (US$333,333). We did not have any investing activities during the three months ended April 30, 2019.

*Financing Activities*

During the three months ended April 30, 2019, our cash provided by financing activities decreased by $4,150,745. During the three months ended April 30, 2019, we received net proceeds of $1,250,000 from issuance of units, consisting of common stock and share purchase warrant, and $276,000 from a promissory note. We also repaid $750,000 of our convertible debentures and paid $250,000 for extension of the maturity of the convertible debentures. During the three months ended April 30, 2018, we received net proceeds of $4,939,975 from convertible debentures and $502,464 from promissory note. We repaid loan payable and promissory notes totaling $15,925 and $749,769, respectively.

We have estimated our expenses and working capital requirements for the next 12 months to be as follows:

|  |  |  |  |
| --- | --- | --- | --- |
|   |   | **Estimated** **Expenses** |   |
| Product manufacture |   | $ | 4,990,000 |   |
| U.S. facility capital expenditures |   |   | 2,000,000 |   |
| Patent maintenance |   |   | 455,000 |   |
| Regulatory |   |   | 250,000 |   |
| Sales and marketing |   |   | 400,000 |   |
| General and administrative |   |   | 4,155,000 |   |
| **Total:** |   | **$** | **12,250,000** |  |

In May 2019, we closed on non-brokered private placements totaling $15 million, a portion of which were used to settle $2.5 million of our convertible debentures and outstanding obligations. The remainder of the proceeds will fund our estimated expenses and working capital requirements for the next 12 months.

Although we are anticipating commercialization to commence on some of our product initiatives over the next 12 months, anticipated revenues may not be initially sufficient to finance our business plan. In addition, if our estimated expenses and working capital requirements for the next 12 months are higher than estimated, additional funds will also be required to fund our business plans. If required, we intend to raise capital through equity and, if necessary, debt financing. We anticipate that the bulk of any additional funding we receive will be in the form of equity financing from the sale of our common stock. In the absence of such financing, we will not be able to carry out our planned development activities. There is no assurance that we will be able to maintain operations at a level sufficient for an investor to obtain a return on his investment in our common stock.

Any modifications to our plans will be based on many factors, including the amount of available capital. Further, the extent to which we carry out our development of planned products is dependent upon the amount of financing available to us.

**Future Financings**

We may require additional financing in order to enable us to proceed with our plan of operations, as discussed above,

|  |
| --- |
|   |
| 29 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

We anticipate revenues on some of our product initiatives to commence over the next 12 months, beginning with sales of micellized CBD Solutions in the European Union, where regulations permit. Should anticipated revenues be less than estimated, we will need to rely on equity sales of our common stock in order to continue to fund our business operations. Issuances of additional shares will result in dilution to our existing stockholders. There is no assurance that we will achieve any additional sales of our equity securities or arrange for debt or other financing to fund our planned business activities.

Except as disclosed above regarding the closing of non-brokered private placements totaling $15 million, we presently do not have any arrangements for additional financing for the expansion of our operations, and no potential lines of credit or sources of financing are currently available for the purpose of proceeding with our plan of operations.

**Inflation**

The amounts presented in the consolidated condensed financial statements do not provide for the effect of inflation on our operations or financial position. The net operating losses shown would be greater than reported if the effects of inflation were reflected either by charging operations with amounts that represent replacement costs or by using other inflation adjustments.

**Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

**Critical Accounting Policies**

The discussion and analysis of our consolidated financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our consolidated financial statements is critical to an understanding of our consolidated financial statements.

*Use of Estimates*

The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.

The Company regularly evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets and assumptions used to determine the fair values of stock-based compensation, warrants and warrants issued with shares units. Estimates and assumptions have also been made on the recoverable amount of intangible assets, fair value of debentures for the purpose of evaluating modification versus extinguishments, fair value of convertible debentures and deferred income tax asset. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

|  |
| --- |
|   |
| 30 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

*Foreign Currency Translation*

The functional currency of the parent entity, Pivot Pharmaceuticals Inc., and the wholly-owned subsidiaries, Pivot Green Stream Health Solutions Inc. and Thrudermic, LLC, is the Canadian dollar. The functional currency of the wholly-owned subsidiary, Pivot Naturals, LLC, is the US dollar.

Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the rates of exchange in place at the balance sheet date. Transactions in currencies other than the functional currency during the year are converted into the functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the consolidated statement of operations and comprehensive loss.

Assets and liabilities of the companies are translated from their respective functional currencies to the reporting currency at the exchange rates at the balance sheet dates, equity accounts are translated at historical exchange rates and revenues and expenses are translated at the average exchange rates in effect during the reporting period. The resulting foreign currency translation adjustment are recorded in other comprehensive loss.

*Financial Instruments and Fair Value Measures*

ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Our financial instruments consist principally of cash, accounts payable and accrued liabilities, due to related parties, convertible debentures, promissory note and acquisition obligation. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

*Equipment*

Equipment are recorded at cost less accumulated depreciation and accumulated impairment losses. Depreciation is recorded using the straight-line method to depreciate the cost of equipment over its estimated useful life of six years. In accordance with ASC 360, “Property, Plant and Equipment”, our company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

|  |
| --- |
|   |
| 31 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

*Intangible Assets*

Intangible assets consists of costs incurred to acquire license, patents and unpatented technology. Intangible assets are considered finite live assets and recorded at cost less accumulated amortization and accumulated impairment. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the asset. Amortization is recorded using the straight-line method and is intended to amortize the intangible assets over their estimated useful lives:

|  |  |
| --- | --- |
| License  | 5 years |
| Patents  | 10 years |
| Unpatented technology  | 10 years |

*Impairment of Intangible Assets*

When facts and circumstances indicate that the carrying value of definite-lived intangible assets may not be recoverable, management assesses the recoverability of the carrying value by preparing estimates of sales and the resulting profit and cash flows expected to result from the use of the asset or asset group and its eventual disposition. If the sum of the expected future cash flows (undiscounted and without interest charges) is less than the carrying amount, we recognize an impairment loss. The impairment loss recognized is the amount by which the carrying amount of the asset or asset group exceeds the fair value. We use a variety of valuation methodologies to determine the fair value of these assets, including discounted cash flow models.

*Stock-Based Compensation*

The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock-Based Compensation to determine the fair value of share options and account for stock-based compensation expenses using an estimated forfeiture rate at the time of grant and revising the rate, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Stock-based compensation expenses are recorded net of estimated forfeitures such that expenses are recorded only for those share-based awards that are expected to vest. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

*Income Taxes*

Our company accounts for income taxes using the asset and liability method in accordance with ASC 740, “Income Taxes”. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. Our company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. As of April 30, 2019 and January 31, 2019, our company did not have any amounts recorded pertaining to uncertain tax positions.

Our company files federal and provincial income tax returns in Canada. Our company recognizes interest and penalties related to uncertain tax positions in tax expense. During the three months ended April 30, 2019 and 2018, there were no charges for interest or penalties.

*Recent Accounting Pronouncements*

Our company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

|  |
| --- |
|   |
| 32 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**Item 3. Quantitative and Qualitative Disclosure About Market Risk**

As a “smaller reporting company”, we are not required to provide the information required by this Item.

**Item 4. Controls and Procedures**

*Evaluation of Disclosure Controls and Procedures*

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer (our principal executive officer) and our chief financial officer (principal financial officer and principal accounting officer), as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer (our principal executive officer) and our chief financial officer (principal financial officer and principal accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of quarter covered by this report. Based on the evaluation of these disclosure controls and procedures our chief executive officer (our principal executive officer) and our chief financial officer (principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective.

*Changes in Internal Controls*

During the quarter covered by this report there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

|  |
| --- |
|   |
| 33 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PART II – OTHER INFORMATION**

**Item 1. Legal Proceedings**

In April 2019, the employment of two of the Company’s employees in Pivot Naturals, including the President of Pivot Naturals, which was pursuant to written employment contracts, terminated. A demand for arbitration has been made by these former employees along with a draft arbitration complaint that alleges claims for breach of the written employment contracts, fraud, illegal retaliation and tortious discharge in violation of public policy seeking, among other things, recovery of accrued and unpaid salary and wages in the total amount of US$213,179 and contractual severance amounts totaling US$475,000 alleged to be due and owing on their alleged involuntary termination, as well as other general and punitive damages. The Company intends to vigorously defend these claims and file cross-claims against the former employees for breach of contract and related tort claims. In June 2019, the Company paid all accrued and unpaid salary and wages to these former employees. The Company has not accrued contractual severance amounts totaling US$475,000 as of April 30, 2019 as management is not able to assess the likelihood of payment.

Additionally, the Company has filed suit in British Columbia against the former President and former Director of Pivot Naturals for declaratory relief and related matters concerning control and use of Pivot Assets.

Other than the claims and suits described above, there are no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to our interest.

**Item 1A. Risk Factors**

As a “small reporting company”, we are not required to provide the information required by this Item.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

Other than as set out below, we did not sell any equity securities which were not registered under the Securities Act during the three months ended April 30, 2019 that were not otherwise disclosed on our quarterly reports on Form 10-Q or our current reports on Form 8-K filed during the three months ended April 30, 2019.

Effective May 30, 2019, we closed a private placement for an aggregate of 13,868,000 units, consisting of one common share and one share purchase warrant, at price of $0.25 per unit, for gross proceeds of $3,467,000. Each share purchase warrant entitles the holder to purchase one common share at a price of $0.35 per share and has an expiry term of two (2) years. In connection with this private placement, we issued 13,868,000 common shares and 13,868,000 share purchase warrants to thirty-two (32) non U.S. persons (as that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933.

Advisory fees consisted of the issuance of 4,200,000 units, consisting of one common share and one share purchase warrant, with each share purchase warrant entitling the holder to purchase one common share at a price of $0.35 per share and has an expiry term of two (2) years. In connection with the advisory fees, we issued 4,200,000 common shares and 4,200,000 share purchase warrants to seven (7) non U.S. persons (as that term as defined in Regulation S of the Securities Act of 1933) and one (1) U.S. person (as that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

On May 30, 2019, we appointed Mr. Krisztian Toth as our Director and Chairman. On June 6, 2019, we appointed Mr. Ken Kessler as our Director. Also on June 6, 2019, we accepted the resignation of Dr. Patrick Frankham as Director.

|  |
| --- |
|   |
| 34 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**Item 6. Exhibits**

|  |  |  |
| --- | --- | --- |
| **Exhibit Number** |   | **Description** |
| **(3)** |   | **Articles of Incorporation and Bylaws**  |
| [3.1](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-1.htm) |  | [Articles of Incorporation 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-1.htm)  |
| [3.2](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-2.htm) |  | [“Company Act” Memorandum of 649186 B.C. Ltd. Certificate of Amendment (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-2.htm)  |
| [3.3](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-3.htm) |  | [Certificate of Filing of 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-3.htm)  |
| [3.4](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-4.htm) |   | [Certificate of Incorporation of 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-4.htm)  |
| [3.5](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-5.htm) |  | [Certificate of Name Change of 649186 B.C. Ltd. to Xerxes Health Corp. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-5.htm)  |
| [3.6](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-6.htm) |  | [Transition Application of Xerxes Health Corp. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-6.htm)  |
| [3.7](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-7.htm) |  | [Certificate of Name Change of Xerxes Health Corp. to Neurokine Pharmaceuticals Inc. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-7.htm)  |
| [3.8](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-8.htm) |  | [Notice of Alteration to Authorized Share Structure (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-8.htm)  |
| [3.9](http://www.sec.gov/Archives/edgar/data/1464165/000151116414000332/exhibit31noticeofalterati001.jpg) |  | [Notice of Alteration to Authorized Share Structure (incorporated by reference from our Current Report on Form 8-K filed on June 4, 2014)](http://www.sec.gov/Archives/edgar/data/1464165/000151116414000332/exhibit31noticeofalterati001.jpg) |
| [3.10](http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_31.htm) |  | [Form 11 Notice of Alteration (incorporated by reference from our Current Report on Form 8-K filed on October 9, 2014)](http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_31.htm) |
| [3.11](http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_32.htm) |  | [Articles (incorporated by reference from our Current Report on Form 8-K filed on October 9, 2014)](http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_32.htm) |
| [3.12](http://www.sec.gov/Archives/edgar/data/1464165/000147793215002579/neukf_ex31.htm) |  | [Notice of Alteration changing name to Pivot Pharmaceuticals Inc. (incorporated by reference to our Current Report on Form 8-K filed on April 17, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215002579/neukf_ex31.htm) |
| [3.13](http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex313.htm) |  | [Certificate of Name Change of Neurokine Pharmaceuticals Inc. to Pivot Pharmaceuticals Inc. (filed on June 17, 2015 with our Annual Report on Form 10K/A)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex313.htm) |

|  |
| --- |
|   |
| 35 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

|  |  |  |
| --- | --- | --- |
| **Exhibit Number** |   | **Description** |
| **(10)** |   | **Material Contracts**  |
| [10.1](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-2.htm) |   | [Non-Exclusive License Agreement with Globe Laboratories Inc. dated June 17, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-2.htm)  |
| [10.2](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-8.htm) |   | [Clinical Trial Services Agreement with Virtus Clinical Development (Pty) Limited dated March 1, 2009 (incorporated by reference to our Registration Statement on Form S-1/A filed on March 4, 2010)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-8.htm)  |
| [10.3](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-9.htm) |   | [Master Service Agreement with Northern Lipids Inc. dated October 2, 2007 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-9.htm)  |
| [10.4](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-10.htm) |   | [Assignment of Invention (NK-001) dated January 30, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-10.htm)  |
| [10.5](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-11.htm) |   | [Assignment of Invention (NK-002) dated April 18, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-11.htm)  |
| [10.6](http://www.sec.gov/Archives/edgar/data/1464165/000106299310002584/exhibit10-2.htm) |   | [Subscription Agreement with Ahmad Doroudian (incorporated by reference to our Form 8-K filed on August 12, 2010)](http://www.sec.gov/Archives/edgar/data/1464165/000106299310002584/exhibit10-2.htm)  |
| [10.7](http://www.sec.gov/Archives/edgar/data/1464165/000151116413000559/neurokineadoroudiandebtsettl.htm) |   | [Debt Settlement Subscription Agreement dated September 26, 2013 with Ahmad Doroudian (incorporated by reference to our Quarterly Report on Form 10-Q filed on December 16, 2013)](http://www.sec.gov/Archives/edgar/data/1464165/000151116413000559/neurokineadoroudiandebtsettl.htm) |
| [10.8](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_101.htm) |   | [Director Services Agreement dated February 25, 2015 with Barbara-Jean Bormann-Kennedy (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_101.htm) |
| [10.9](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_103.htm) |   | [Director Services Agreement dated February 25, 2015 with Dr. Patrick Frankham (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_103.htm) |
| [10.10](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_102.htm) |   | [Director Services Agreement dated February 26, 2015 with Dr. Wolfgang Renz (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_102.htm) |
| [10.11](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_104.htm) |   | [Consulting Services Agreement dated February 25, 2015 with Dr. Giora Davidai (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_104.htm) |
| [10.12](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1012.htm) |   | [Director Services Agreement dated November 19, 2015 with Dr. Patrick Frankham (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1012.htm) |
| [10.13](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1013.htm) |   | [Director Services Agreement dated November 19, 2015 with Dr. Wolfgang Renz (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1013.htm) |
| [10.14](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1014.htm) |   | [Consulting Services Agreement dated November 19, 2015 with Dr. Giora Davidai (incorporated by reference to our Quarterly Report on Form 10‑Q filed on December 15, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1014.htm) |
| 10.15 |   | Plan of Merger and Acquisition Agreement between our company and IndUS Pharmaceuticals, Inc., dated November 4, 2015 (incorporated by reference to our Current Report on Form 8‑K filed on November 23, 2015 and our Current Report on Form 8‑K/A filed on February 3, 2016) |
| [10.16](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1016.htm) |   | [Employment Agreement dated November 20, 2015 with Dr. Pravin Chaturvedi (incorporated by reference to our Quarterly Report on Form 10‑Q filed on December 15, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1016.htm) |
| [10.17](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1017.htm) |   | [Employment Agreement dated February 1, 2016 with Dr. Ahmad Doroudian (filed on April 29, 2016 with our Annual Report on Form 10-K)](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1017.htm) |
| [10.18](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1018.htm) |   | [Employment Agreement dated February 1, 2016 with Moira Ong (filed on April 29, 2016 with our Annual Report on Form 10-K)](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1018.htm) |
| [10.19](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1019.htm) |   | [Consulting Services Agreement dated February 1, 2016 with Soho Capital Inc. (filed on April 29, 2016 with our Annual Report on Form 10-K)](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1019.htm) |
| [10.20](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1020.htm) |   | [Convertible debenture agreement dated September 29, 2016 with Avro Capital Partners Inc. (incorporated by reference to our Quarterly Report on Form 10-Q filed on September 14, 2017)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1020.htm) |
| [10.21](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1021.htm) |   | [Exchange Agreement between our company, IndUS Pharmaceuticals, Inc. and Pravin Chaturvedi, dated September 11, 2017 (incorporated by reference to our Current Report on Form 8-K filed on September 12, 2017)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1021.htm) |
| [10.22](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1022.htm) |   | [Licensing Agreement between our company and Altum Pharmaceuticals Inc. dated September 12, 2017 (incorporated by reference to our Current Report on Form 8-K filed on September 12, 2017)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1022.htm) |
| [10.23](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1023.htm) |   | [Debt Forgiveness Agreement dated July 31, 2017 between our company and Dr. Ahmad Doroudian (filed on September 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1023.htm) |
| [10.24](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1024.htm) |   | [Debt Forgiveness Agreement dated July 31, 2017 between our company and Moira Ong (filed on September 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1024.htm) |
| [10.25](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1025.htm) |   | [Debt Forgiveness Agreement dated July 31, 2017 between our company and Soho Capital Inc. (filed on September 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1025.htm) |
| [10.26](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1026.htm) |   | [Debt Settlement Agreement dated September 18, 2017 between our company and Avro Capital Partners, Inc. (filed on December 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1026.htm) |
| [10.27](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1027.htm) |   | [Collaboration and License Agreement dated September 23, 2017 between our company and SolMic GmbH (filed on December 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1027.htm) |
| [10.28](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1028.htm) |   | [Letter of Intent dated November 7, 2017 between our company and Thrudermic LLC (filed on December 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1028.htm) |

|  |
| --- |
|   |
| 36 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

|  |  |  |
| --- | --- | --- |
| [10.29](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1029.htm) |   | [Share Exchange Agreement between our company, ERS Holdings, LLC and the members of ERS Holdings, LLC dated February 10, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1029.htm) |
| [10.30](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1030.htm) |   | [Royalty Agreement between our company and AquaBrew Inc. dated March 1, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1030.htm) |
| [10.31](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1031.htm) |   | [Employment Agreement between our company and Patrick Rolfes dated March 1, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1031.htm) |
| [10.32](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1032.htm) |   | [Share Exchange Agreement between our company, Thrudermic, LLC, Dr. Joseph Borovsky and Dr. Leonid Lurya dated March 2, 3018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1032.htm) |
| [10.33](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1033.htm) |   | [Employment Agreement between our company and Joseph Borovsky dated March 1, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1033.htm) |
| [10.34](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1034.htm) |   | [10% Senior Secured Convertible Debenture (CDN$2,500,000) due March 2, 2019 (CD-1) (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1034.htm) |
| [10.35](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1035.htm) |   | [10% Senior Secured Convertible Debenture (CDN$2,500,000) due March 2, 2019 (CD-2) (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1035.htm) |
| [10.36](http://www.sec.gov/Archives/edgar/data/1464165/000147793218005263/pvotf_ex1036.htm) |   | [10% Senior Secured Convertible Debenture (CDN$1,750,000) due March 2, 2019 (CD-3) (incorporated by reference to our Current report on Form 8-K filed on November 6, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218005263/pvotf_ex1036.htm) |  |
| [10.37](http://www.sec.gov/Archives/edgar/data/1464165/000147793218005263/pvotf_ex1037.htm) |   | [10% Senior Secured Convertible Debenture (CDN$1,750,000) due March 2, 2019 (CD-4) (incorporated by reference to our Current report on Form 8-K filed on November 6, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218005263/pvotf_ex1037.htm) |  |
| 10.38 |   | 10% Senior Secured Convertible Debentures (CDN$1,375,000) due June 1, 2019 (CD-3) |  |
| 10.39 |   | 10% Senior Secured Convertible Debentures (CDN$1,375,000) due June 1, 2019 (CD-4) |  |
| **(31)** |   | **Rule 13a-14(d)/15d-14(d) Certifications**  |  |
| [31.1\*](file:///C%3A%5Cedger%5Cpvotf_ex311.htm) |   | [Section 302 Certification under the Sarbanes-Oxley Act of 2002 of Principal Executive Officer](file:///C%3A%5Cedger%5Cpvotf_ex311.htm) |  |
| [31.2\*](file:///C%3A%5Cedger%5Cpvotf_ex312.htm) |   | [Section 302 Certification under the Sarbanes-Oxley Act of 2002 of Principal Financial Officer](file:///C%3A%5Cedger%5Cpvotf_ex312.htm) |  |
| **(32)** |   | **Section 1350 Certifications**  |  |
| [32.1\*](file:///C%3A%5Cedger%5Cpvotf_ex321.htm) |   | [Section 906 Certification under the Sarbanes-Oxley Act of 2002 of Principal Executive Officer](file:///C%3A%5Cedger%5Cpvotf_ex321.htm) |  |
| [32.2\*](file:///C%3A%5Cedger%5Cpvotf_ex322.htm) |   | [Section 906 Certification under the Sarbanes-Oxley Act of 2002 of Principal Financial Officer](file:///C%3A%5Cedger%5Cpvotf_ex322.htm) |  |
| **99** |   | **Additional Exhibits** |
| [99.1](http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex991.htm) |   | [Audit Committee Charter (filed on June 17, 2015 with our Annual Report on Form 10K/A)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex991.htm) |
| [99.2](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007379/pvotf_def14a.htm) |   | [Stock Option Plan (filed on November 25, 2015 with our Definitive Proxy Statement on Schedule 14A)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007379/pvotf_def14a.htm) |
| **101\*** |   | **Interactive Data Files** |  |
| 101.INS |   | XBRL Instance Document |  |
| 101.SCH |   | XBRL Taxonomy Extension Schema Document |  |
| 101.CAL |   | XBRL Taxonomy Extension Calculation Linkbase Document |  |
| 101.DEF |   | XBRL Taxonomy Extension Definition Linkbase Document |  |
| 101.LAB |   | XBRL Taxonomy Extension Label Linkbase Document |  |
| 101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document |  |

\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*\* Filed herewith*

|  |
| --- |
|   |
| 37 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|  |  |  |
| --- | --- | --- |
|  |  |   |
|  | **PIVOT PHARMACEUTICALS INC.**  |   |
|  | (Registrant)  |   |
|   |   |   |
| Dated: June 17, 2019 | */s/ Patrick Frankham* |   |
|  | **Dr. Patrick Frankham**  |   |
|  | Chief Executive Officer and Director |   |
|  | (Principal Executive Officer)  |   |
|   |   |   |
| Dated: June 17, 2019 | */s/ Moira Ong* |   |
|  | **Moira Ong**  |   |
|  | Chief Financial Officer  |   |
|  | (Principal Financial Officer and Principal Accounting Officer) |   |

|  |
| --- |
|   |
| 38 |

**EXHIBIT 31.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Patrick Frankham, certify that:

|  |  |
| --- | --- |
| 1. | I have reviewed this quarterly report on Form 10-Q of Pivot Pharmaceuticals Inc.; |
|   |   |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|   |   |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|   |   |
| 4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |

|  |  |  |
| --- | --- | --- |
|   | (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|   |   |   |
|   | (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|   |   |   |
|   | (c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|   |   |   |
|   | (d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |

|  |  |
| --- | --- |
| 5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |

|  |  |  |
| --- | --- | --- |
|   | (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|   |   |   |
|   | (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |

|  |  |
| --- | --- |
| Date: June 17, 2019 |   |
|   |   |
| */s/ Patrick Frankham* |   |
| Patrick Frankham |   |
| Chief Executive Officer and Director (Principal Executive Officer) |   |

**EXHIBIT 31.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Moira Ong, certify that:

|  |  |
| --- | --- |
| 1. | I have reviewed this quarterly report on Form 10-Q of Pivot Pharmaceuticals Inc.; |
|   |   |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|   |   |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|   |   |
| 4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |

|  |  |  |
| --- | --- | --- |
|   | (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|   |   |   |
|   | (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|   |   |   |
|   | (c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|   |   |   |
|   | (d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |

|  |  |
| --- | --- |
| 5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |

|  |  |  |
| --- | --- | --- |
|   | (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|   |   |   |
|   | (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |

|  |  |
| --- | --- |
| Date: June 17, 2019 |   |
|   |   |
| */s/ Moira Ong* |   |
| Moira Ong |   |
| Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |   |

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Patrick Frankham, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

|  |  |
| --- | --- |
| (1) | the Quarterly Report on Form 10-Q of Pivot Pharmaceuticals Inc. for the period ended April 30, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|   |   |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Pivot Pharmaceuticals Inc. |

|  |  |  |
| --- | --- | --- |
| Dated: June 17, 2019 |  |  |
|  |  |  |
|  |   | */s/ Patrick Frankham* |   |  |
|  |   | Patrick Frankham |
|  |   | Chief Executive Officer and Director (Principal Executive Officer) |
|  |   | Pivot Pharmaceuticals Inc.  |

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Pivot Pharmaceuticals Inc. and will be retained by Pivot Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Moira Ong, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

|  |  |
| --- | --- |
| (1) | the Quarterly Report on Form 10-Q of Pivot Pharmaceuticals Inc. for the period ended April 30, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|   |   |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Pivot Pharmaceuticals Inc. |

|  |  |  |
| --- | --- | --- |
| Dated: June 17, 2019 |  |  |
|  |  |  |
|  |   | */s/ Moira Ong* |   |  |
|  |   | Moira Ong |
|  |   | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
|  |   | Pivot Pharmaceuticals Inc. |

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Pivot Pharmaceuticals Inc. and will be retained by Pivot Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.